Therapeutics

From day one, our goal has been to leverage our unique proprietary technologies and know-how to build a company that would bring safer, more cost-effective and more convenient therapeutic products to under served patient populations in both existing and emerging markets. Below you will find the latest updates for our leading indications including clinical trial results, FDA & EMA designations.

  • Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th ERA/EDTA congress

    Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th ERA/EDTA congress

    Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th fibrosis at the 56th ERA/EDTA congress

    Read Article
  • Prometic presents new PBI-4050 and Ryplazim (plasminogen) data on lung fibrosis at the 2019 ATS conference

    Prometic presents new PBI-4050 and Ryplazim (plasminogen) data on lung fibrosis at the 2019 ATS conference

    Prometic today announced the presentation of three scientific posters on the Company’s lead small molecule and plasma-derived drug product candidates, respectively PBI-4050 and Ryplazim™.

    Read Article
  • Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome

    Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome

    The protocol for the Phase 3 clinical trial will be designed to meet expectations from both the U.S and EU regulatory agencies.

    Read Article
  • PBI-4050 KOL Event: Alstrom & NASH Sept 7 2018

    PBI-4050 KOL Event: Alstrom & NASH Sept 7 2018

    Prometic is hosting a key opinion leader luncheon to discuss our lead candidate PBI-4050 for Alstrom Syndrome and a promising therapeutic candidate for NASH

    Read PDF
  • Find out more about PBI-4050

    Learn More
  • Prometic announces second annual plasminogen deficiency awareness week

    Prometic announces second annual plasminogen deficiency awareness week

    This initiative, sponsored by Prometic, aims to raise awareness and improve understanding of this rare disease and its effects. Plasminogen Deficiency Awareness Week is a free 4-day online event

    Read Article
  • Prometic announces positive feedback from FDA type-c meeting on Ryplazim (plasminogen) BLA

    Prometic announces positive feedback from FDA type-c meeting on Ryplazim (plasminogen) BLA

    Implementation plan for additional analytical assays and in-process controls confirmed and PLI finalizing process performance qualification (PPQ) protocol in order to proceed with the manufacturing

    Read Article
  • Prometic’s Plasminogen (Ryplazim™) granted orphan drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF)

    Prometic’s Plasminogen (Ryplazim™) granted orphan drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF)

    In a gold-standard animal model proven to emulate pulmonary fibrosis in humans, Prometic’s Plasminogen (Ryplazim™) performed favorably compared to recently- approved IPF drugs to treat this condition.

    Read Article
  • Discover more about Plasminogen

    Inform Me
  • loading
    Loading More...